Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Trius Therapeutics Inc Secures $25 Million Committed Equity Financing Facility With Terrapin Opportunity, L.P.
Trius Therapeutics Inc announced that it has obtained a committed equity financing facility under which it may from time to time sell up to $25 million of its registered common stock to Terrapin Opportunity, L.P., over a 24-month period. Trius is not obligated to utilize any of the $25 million facility and remains free to enter into and consummate other equity and debt financing transactions, subject to certain restrictions.
Latest Developments for Trius Therapeutics Inc
- Trius Therapeutics Inc Announces Pricing Of Underwritten Public Offering
- Trius Therapeutics Inc' Antibiotic Tedizolid Demonstrates High Efficacy In Patients With Cellulitis
- Trius Therapeutics Inc Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares For Common Stock Offering
- Trius Therapeutics, Inc. Prices Public Offering of Common Stock
Latest Key Developments in Biotechnology
- Oramed Pharmaceuticals Inc Receives FDA Clearance To Initiate Oral Insulin Trials In U.S.
- Cordlife Group Ltd Announces Proposed Acquisition Of CS Cell Technologies Pte. Ltd, Cordlife Stem Cell Technology Limited And Certain Assets Of P.T. Cordlife Indonesia From Cordlife Limited
- Stemline Therapeutics Inc Prices $60 Million Public Offering Of Common Stock
- Ambit Biosciences Corp Announces Pricing Of Initial Public Offering
- Share this
- Link this
- Digg this
Follow Reuters